Eunsung Jun1, Song Cheol Kim2, Ki Byung Song3, Dae Wook Hwang3, Jae Hoon Lee3, Sang Hyun Shin3, Seung Mo Hong4, Kwang-Min Park3, Young-Joo Lee3. 1. Department of Biomedical Sciences, University of Ulsan College of Medicine, Seoul, South Korea; Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, South Korea. 2. Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, South Korea. Electronic address: drksc@amc.seoul.kr. 3. Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, South Korea. 4. Department of Pathology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, South Korea.
Abstract
BACKGROUND: Chromogranin A has recently been recommended as the most practical tumor marker in patients with pancreatic neuroendocrine tumors. However, the diagnostic effectiveness of circulating chromogranin A levels remains controversial. Here, we aimed to assess the clinical diagnostic value of plasma chromogranin A levels for pancreatic neuroendocrine tumors. METHODS: Between June 2012 and June 2015, 110 consecutive patients with a suspected pancreatic neuroendocrine tumor were prospectively enrolled. We evaluated the diagnostic value of the chromogranin A assay for differentiating pancreatic neuroendocrine tumors from other tumors. The plasma chromogranin A levels in the pancreatic neuroendocrine tumor patients were examined according to various clinicopathologic factors. RESULTS: A total of 65 patients were diagnosed as having pancreatic neuroendocrine tumors, whereas 45 had other tumors. The median chromogranin A level in pancreatic neuroendocrine tumor cases was higher than that in cases of other tumors (pancreatic neuroendocrine tumors: 126.62 ng/mL, other tumors: 69.82 ng/mL). The sensitivity, specificity, and accuracy of the chromogranin A assay for pancreatic neuroendocrine tumor diagnosis were 49.2%, 77.8%, and 60.9%, respectively. The chromogranin A levels after operative resection were reduced or were confirmed as being within the normal range (78.9%) in most cases. Moreover, the chromogranin A level in pancreatic neuroendocrine tumors cases was correlated with tumor size based on comparisons with other tumors in the pancreas (P = .038). The sensitivity, specificity, and accuracy of the chromogranin A assay for large tumors were greater, at 64.3%, 100.0%, and 81.5%, respectively. CONCLUSION: In clinical settings, the identification of pancreatic neuroendocrine tumors is vital for the development of therapeutic strategies. In large pancreatic tumors, the measurement of chromogranin A levels is very useful for distinguishing pancreatic neuroendocrine tumors from other tumors in the pancreas.
BACKGROUND:Chromogranin A has recently been recommended as the most practical tumor marker in patients with pancreatic neuroendocrine tumors. However, the diagnostic effectiveness of circulating chromogranin A levels remains controversial. Here, we aimed to assess the clinical diagnostic value of plasma chromogranin A levels for pancreatic neuroendocrine tumors. METHODS: Between June 2012 and June 2015, 110 consecutive patients with a suspected pancreatic neuroendocrine tumor were prospectively enrolled. We evaluated the diagnostic value of the chromogranin A assay for differentiating pancreatic neuroendocrine tumors from other tumors. The plasma chromogranin A levels in the pancreatic neuroendocrine tumorpatients were examined according to various clinicopathologic factors. RESULTS: A total of 65 patients were diagnosed as having pancreatic neuroendocrine tumors, whereas 45 had other tumors. The median chromogranin A level in pancreatic neuroendocrine tumor cases was higher than that in cases of other tumors (pancreatic neuroendocrine tumors: 126.62 ng/mL, other tumors: 69.82 ng/mL). The sensitivity, specificity, and accuracy of the chromogranin A assay for pancreatic neuroendocrine tumor diagnosis were 49.2%, 77.8%, and 60.9%, respectively. The chromogranin A levels after operative resection were reduced or were confirmed as being within the normal range (78.9%) in most cases. Moreover, the chromogranin A level in pancreatic neuroendocrine tumors cases was correlated with tumor size based on comparisons with other tumors in the pancreas (P = .038). The sensitivity, specificity, and accuracy of the chromogranin A assay for large tumors were greater, at 64.3%, 100.0%, and 81.5%, respectively. CONCLUSION: In clinical settings, the identification of pancreatic neuroendocrine tumors is vital for the development of therapeutic strategies. In large pancreatic tumors, the measurement of chromogranin A levels is very useful for distinguishing pancreatic neuroendocrine tumors from other tumors in the pancreas.
Authors: Roopa Mehta; César Ernesto Lam-Chung; José Miguel Hinojosa-Amaya; Paola Roldán-Sarmiento; Maria Fernanda Guillen-Placencia; Gerladine Villanueva-Rodriguez; Oscar Alfredo Juarez-Leon; Jefsi Leon-Domínguez; Mariana Grajales-Gómez; Jose Luis Ventura-Gallegos; Andrés León-Suárez; Francisco J Gómez-Pérez; Daniel Cuevas-Ramos Journal: Front Endocrinol (Lausanne) Date: 2020-08-13 Impact factor: 5.555
Authors: Alessandra Pulvirenti; Deepthi Rao; Caitlin A Mcintyre; Mithat Gonen; Laura H Tang; David S Klimstra; Martin Fleisher; Lakshmi V Ramanathan; Diane Reidy-Lagunes; Peter J Allen Journal: HPB (Oxford) Date: 2018-10-23 Impact factor: 3.647